stockportfolio.pro
Amneal Pharmaceuticals, Inc. Net Income 2016–2025
Amneal Pharmaceuticals, Inc. (AMRX) annual net income by fiscal year, computed from SEC filings.
| Fiscal year | Net Income | Net margin | Change (YoY) |
|---|---|---|---|
| FY 2025 | $72.06M | 2.4% | +161.6% |
| FY 2024 | $-116.89M | -4.2% | -39.2% |
| FY 2023 | $-83.99M | -3.5% | +69.0% |
| FY 2022 | $-270.58M | -12.2% | -2155.6% |
| FY 2021 | $13.16M | 0.6% | -80.6% |
| FY 2020 | $67.79M | 3.4% | +111.2% |
| FY 2019 | $-603.57M | -37.1% | -2957.0% |
| FY 2018 | $-19.74M | -1.2% | — |
| FY 2017 | $0 | 0.0% | — |
| FY 2016 | $0 | 0.0% | — |
Source: Amneal Pharmaceuticals, Inc. SEC filings — income statement (10-K). Refreshed nightly.
See the full picture for Amneal Pharmaceuticals, Inc.
Complete income statement, balance sheet and cash flow with trend on every row, 48 quarters, ratios, health checks, and Ask — the SEC-grounded research assistant.
Open the interactive view — freeAmneal Pharmaceuticals, Inc. — frequently asked questions
What is Amneal Pharmaceuticals, Inc.'s net income?
Amneal Pharmaceuticals, Inc. (AMRX) reported net income of $72.06M for fiscal year 2025, per its SEC filings.
Where does this data come from?
Figures are computed from Amneal Pharmaceuticals, Inc.'s official SEC filings (income statement (10-K)), refreshed nightly. Not investment advice.